Molecular immunology and genetics of inflammatory muscle diseases

Archives of Neurology

Volumn 55, Issue 12, 1998, Pages 1509-1512

  Dalahas, Mflrinos C ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; MESSENGER RNA; PROTEIN BCL 2; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CELL VACUOLE; CYTOKINE RELEASE; DERMATOMYOSITIS; GENE REARRANGEMENT; HUMAN; IMMUNOPATHOLOGY; INCLUSION BODY MYOSITIS; INFLAMMATORY CELL; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL;

EID: 0031647766     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neural. 1995; 37(suppl 1):S74-S86.
2. Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndromes. In: Engel AG, Franzini-Armstrong C, eds. Myology. 2nd ed. New York, NY: McGraw-Hill Book Co; 1994:1335-1383.
3. Mantegazza R, Andreetta f, Bernasconi P, et al. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis: restricted V α/β rearrangements may indicate antigen-driven selection. J Clin Invest. 1993;91: 2880-2886.
4. O'Hanlon TP, Dalakas MC, Plotz PH, Miller FW. Predominant TCR-αβ variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol. 1994:152:2569-2576.
5. + T cells. JExpMed. 1995;181:1863-1868.
6. O'Hanlon TP, Dalakas MC, Plotz PH, Miller FW. The a T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscleinfiltrating lymphocytes. J Autoimmun. 1994:7:321-333.
7. Bender A, Behrens L, Engel AG, Hohlfeld R. T-cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol. 1998:84:86-91.
8. Amemiya K, Dalakas MC. The T-cell receptor repertoire of endomysial lymphocytes in patients with inclusion body myositis (IBM) remains restricted overtime: studies in repeated muscle biopsies [abstract]. Neurology. 1998:50:204.
9. Koffman BM, Sivakumar K, Simonis T, Stronek D, Dalakas MC. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol. 1998:84:139-142.
10. Koffman BM, Rugiero M, Dalakas MC. Autoimmune diseases and autoantibodies associated with sporadic inclusion body myositis. Muscle Nerve. 1998:21:115-117.
11. Hines KL, Kulkarni AB, McCarthy JB, et al. Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor 1 knockout mice. Proc NatlAcad Sei USA.) 1994;91:5187-5191,
12. Confalonieri P, Bernasconi P, Cornelio F, Mantegazza R. Transforming growth factor-1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate. JNeuropatholExp fJeurol. 1997:56:479-484.
13. Dalakas MC, lila I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. NEnglJMed. 1993:329:1993-2000.
14. Goldgaber D, Harris HW, Hla T, et al. Interleukin 1 regulates synthesis of amyloid -protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A. 1989:86:7606-7610.
15. Griffin WS, Sheng JG, Roberts GW, Mrak RE. lnterleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol. 1995:54:276-281.
16. Semino-Mora C, Dalakas MC. Upregulation of IL-1 mRNA in inclusion body myositis (IBM) and co-expression with p-amyloid precursor protein: a mechanism for amyloid deposits [abstract]. Neurology. 1998;50:204.
17. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sei USA.) 992;89:10075-10078.
18. Goebels N, Michaelis D, Engelhard! M, et al. Differential expression of perform in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest. 1996:97:2905-2910.
19. Behrens L, Bender A, Johnson MA, Hohlfeld R. Cytotoxic mechanisms inflammatory myopathies: co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain. 1997:120:929-938.
20. Schneider C, Gold R, Dalakas MC, et al. MHC class l-mediated cytotoxicity does not induce apoptosis in muscle fibers nor inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol. 1996:55:1205-1209.
21. Sivakumar K, Dalakas MC. Inclusion body myositis and myopathies. CurrOpin Neurol. 1997:10:413-420.
22. Mitrani-Rosenbaum S, Argov Z, Blumenfeld A, Seidman CE, Seidman JG. Hereditary inclusion body myopathy maps to chromosome 9p1 -q1. Hum Mol Genet. 1996:5:159-163.